CARGO Therapeutics
NEWS
CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a mid-stage trial of its lead program, firi-cel.
The handful of biotechs that went public in 2023 fared well, providing hope to a cautiously optimistic sector.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
The cell therapy-focused biotech will use most of the net proceeds from its initial public offering to fund Phase II clinical trials for its lead program, a novel CAR T-cell candidate.
IN THE PRESS
JOBS